P74

Proposed Changes to BenevolentAI’s Board Composition

Retrieved on: 
Monday, April 15, 2024
Technology, Research, Finance, Health Technology, Professional Services, Biotechnology, Health, Science, Artificial Intelligence, Annual general meeting, CFO, Cure, Investment, AI, Neo-noir, Partnership, Business, Growth, Corporate development, GI Partners, BAI, Intellectual property, Drug discovery, LifeArc, AIM, Trust, Amphisbaena, Nomination, Therapy, Euronext Amsterdam, Abcam, P74, Research and development, Trustee, Artificial intelligence, Observation, Chairperson, Digital, Recipharm, Partner, Government, Sale, The Carlyle Group, Business development, Accel-KKR, Senior, Acquisition, F2G, Risk, Audit, AGM, Oxford Nanopore Technologies, Management

Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.

Key Points: 
  • Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.
  • Subject to their appointment at the AGM, it is proposed that Mr. Allen acts as Chair and Mr. Mulvany acts as Deputy Chair of the Board.
  • Together with the rest of the Board, they will support Chief Executive Dr. Jeorg Moeller and his team on implementing the Company’s strategy.
  • He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of LifeArc, a leading UK medical research charity.

Merck Global Health Innovation Fund and P74 Ventures Make Strategic Investment in TransVoyant for Intelligent, ‘Self Aware’ Supply Chain Platform 

Retrieved on: 
Tuesday, December 13, 2022
IOT (Internet of Things), Data Management, Other Health, Technology, Finance, Pharmaceutical, Professional Services, Venture Capital, Artificial Intelligence, Transport, Other Technology, Software, Logistics, Supply Chain Management, Networks, Health, MSD, Fund, Partner, ConvaTec, Elijah Cummings Lower Drug Costs Now Act, Ecosystem, Algorithm, HCP, Automation, Data science, Health, Patient, P74, OT, McKesson Corporation, Disease, DSM, Temperature, IOT, Organization, Pharmaceutical industry, Fine chemical, Merck, UnitedHealth Group

TransVoyant, the worlds only global intelligent supply chain execution platform, announced it has closed its first strategic growth equity financing co-led by Merck Global Health Innovation Fund (MGHIF) and P74 Ventures, bringing the companys total funding to more than $30 million.

Key Points: 
  • TransVoyant, the worlds only global intelligent supply chain execution platform, announced it has closed its first strategic growth equity financing co-led by Merck Global Health Innovation Fund (MGHIF) and P74 Ventures, bringing the companys total funding to more than $30 million.
  • As supply chains expand and become more complex, TransVoyants capabilities provide a potential game-changer for biopharmaceutical manufacturers, said Joe Volpe, Managing Director, Global Health Innovation Fund and General Manager Global Health Innovation PE Fund, LLC.
  • TransVoyants autonomic global supply chain platform tracks material, manufacturing, and product behavioralong with temperature and other environmental factorsto maintain product quality, regulatory compliance, and customer trust.
  • TransVoyants proprietary platform and algorithms were born during complex, real-time national security and global supply chain challenges, said Jeremy Sohn, founder of P74 Ventures.